NASDAQ · INKT
MiNK Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for INKT: Nov 13, 2026
MiNK Therapeutics, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.5. The reported EPS for the same quarter last year was $-0.65.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.50 | $-0.35 | $-0.65 | 2 |
| Dec 2026 | $-0.51 | $-0.39 | $-0.63 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Zacks- RTTNews · Sep 30, 9:28 AM EDTMiNK Selected For ARPA-H Program To Advance Room-Temperature Cell Therapy(RTTNews) – Wednesday, MiNK Therapeutics (INKT) said its agenT-797 iNKT cell therapy platform was selected for an ARPA-H-funded initiative aimed at enabling room-temperature storage and transport of cell therapies.
- The Motley Fool · Aug 13, 11:28 PM EDTMiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 13, 12:04 PM EDTMiNK Therapeutics Q2 Earnings Call HighlightsMiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.
- Zacks · Jul 16, 12:24 PM EDTHere's Why You Should Add INKT Stock to Your Portfolio NowMiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.
- RTTNews · May 29, 2:27 AM EDTTop Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest(RTTNews) – In Thursday's list of gainers, we highlight SciSparc, which received the regulatory go-ahead to acquire a stake in a private Israeli technology company, Co-Diagnostics, which extended its rally for the third straight day, and Tevogen, which is making continued progres
- The Motley Fool · May 15, 11:41 AM EDTMiNK (INKT) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · May 15, 11:38 AM EDTMiNK (INKT) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 15, 10:12 AM EDTMiNK Therapeutics Q1 Earnings Call HighlightsMiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial resul
- NASDAQ.com · May 14, 4:00 PM EDTPre-Market Earnings Report for May 15, 2026 : RBC, HTHT, SGML, SPRY, AZ, LUCD, MHH, INKT, PAVM, SURG, LFWD, SLEThe following companies are expected to report earnings prior to market open on 05/15/2026. Visit our Earnings Calendar for a full list of expected earnings releases.RBC Bearings Incorporated (RBC)is reporting for the quarter ending March 31, 2026. The machinery company's consen
- NASDAQ.com · Mar 30, 4:00 PM EDTPre-Market Earnings Report for March 31, 2026 : MKC, SNX, FDS, TE, CHA, BITF, HDL, ALTI, JILL, INKT, SNYR, AMSThe following companies are expected to report earnings prior to market open on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases.McCormick & Company, Incorporated (MKC)is reporting for the quarter ending February 28, 2026. The food compan
- RTTNews · Mar 10, 7:48 AM EDTMiNK Announces Collaboration To Advance PRAME-Targeted INKT Cell Therapy For Pediatric Cancers(RTTNews) – Shares of MiNK Therapeutics Inc. (INKT) are up by 73% in the pre-market following the announcement of a strategic collaboration with C-Further, an international pediatric oncology consortium, to advance a PRAME-targeted iNKT cell therapy for children with cancer.
- RTTNews · Feb 4, 1:27 AM ESTMiNK Therapeutics Presents Data Supporting Allo-iNKT Cell Therapy In IPF At Keystone Symposia(RTTNews) – MiNK Therapeutics (INKT), a clinical-stage company, said new translational data supporting the role of invariant natural killer T or iNKT cells in idiopathic pulmonary fibrosis or IPF were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for MiNK Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.